Last updated 2026-09-03
Total raised
—
Stage
Pre-Funding
Founded
2019
Headcount
6
HQ
Be'er Sheva, Israel
Sector
Drugs Discovery & Development
About
Molbrick is a startup developing novel antimicrobial agents to treat drug-resistant mycobacteria. It has designed small-molecule target cellular compartments that are essential for DNA replication. Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
Offices
Be'er Sheva, Israel · HQ / main office
Q&A
- What is Molbrick's primary focus?
- Molbrick is a startup developing novel antimicrobial agents to treat drug-resistant mycobacteria.
- What is the core technology behind Molbrick's platform?
- Molbrick has designed small-molecule target cellular compartments that are essential for DNA replication. The platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
- When was Molbrick founded?
- Molbrick was founded in January 2019.
- Where is Molbrick headquartered?
- Molbrick is headquartered in Be'er Sheva, South District, Israel.
- What is Molbrick's current funding stage?
- Molbrick is currently in the Pre-Funding stage.
- What sector does Molbrick primarily operate in?
- Molbrick's primary sector is Health Tech & Life Sciences.
- What is the product stage of Molbrick's offerings?
- Molbrick's product is in the R&D stage.
Highlights
Verified
Tags
pharmaceuticalsmicrobiology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019-1 |
|---|---|
| Employees (exact) | 6 |